Construction has already begun on the Ozempic-producer’s new Danish production facility and 40,000m² warehouse.

STOCKHOLM (Reuters) -Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense ...

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, said Monday it was investing 8.5 billion kroner ($1.2 billion) to build a new factory in ...

The general mood among these heavyweight investors is divided, with 50% leaning bullish and 31% bearish. Among these notable ...

Novo Nordisk is laying out 8.5 billion Danish kroner (about $1.2 billion) to establish a brand-new manufacturing plant in Odense, Denmark, where the company eventually plans to hire on 400 ...

Analysts have set 12-month price targets for Novo Nordisk, revealing an average target of $145.25, a high estimate of $160.00 ...

STOCKHOLM/LONDON, Dec 16 (Reuters) - Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the production of rare disease drugs ...

The 40,000-square-metre (430,000-square-feet) production facility and warehouse in Odense "marks the first time in this century that Novo Nordisk breaks ground in Denmark by establishing a new ...